Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bispecific antibody (anti-BCMA)
- Development stage
- Unknown
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Anti-BCMA bispecific antibodies represent a class of cancer immunotherapies designed to treat multiple myeloma. These dual-targeting molecules simultaneously bind to B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells, and CD3 on T cells. By bridging these two cell types, the bispecific antibody redirects and activates cytotoxic T lymphocytes to selectively target and lyse the myeloma cells. Approved agents in this class, such as teclistamab and elranatamab, have demonstrated significant efficacy in patients with relapsed or refractory multiple myeloma, providing an off-the-shelf treatment option.
- Other names
- anti-BCMA bispecific antibodyanti-BCMA x anti-CD3 bispecific antibodyBCMA x CD3 bispecific antibodyBCMA-directed bispecific antibody
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on bispecific antibody (anti-BCMA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bispecific antibody (anti-BCMA).